论文部分内容阅读
目的:评价复发/难治性血液肿瘤患者在未缓解状态下直接采用异基因干细胞移植(allogeneic-peripheral hemopoietic stem cell transplantation,Allo-PBSCT)后,序贯输注体外培养获得的供者细胞因子诱导的杀伤(cytokine induced killer,CIK)细胞以防治肿瘤复发的疗效及并发症。方法:共收集9例复发/难治性的血液肿瘤患者,均在未缓解状态下直接进行Allo-PBSCT;在患者造血重建后,利用血细胞分离机采集供者外周血中的单个核细胞,体外培养成CIK细胞,分数次输注给患者,观察治疗情况,不良反应及预后。结果:9例患者均顺利造血重建,移植后均获得完全缓解;CIK细胞输注后,4例患者发生移植物抗宿主病,加强免疫抑制治疗后均获好转,1例患者于移植后59d死于感染,其余患者现已中位随访9.2(2～20)个月,生活状况良好。结论:Allo-PBSCT序贯输注供者CIK细胞治疗具有较好的疗效,可以挽救治疗复发/难治性血液肿瘤患者,值得进一步扩大病例研究。
OBJECTIVE: To evaluate the effect of donor cytokines induced by sequential infusion in vitro after direct allogeneic-peripheral hemopoietic stem cell transplantation (Allo-PBSCT) in patients with relapsed / refractory hematological malignancies Of cytokine induced killer (CIK) cells to prevent and treat the efficacy and complications of tumor recurrence. Methods: A total of 9 patients with recurrent / refractory hematological tumors were collected and allo-PBSCT was performed directly without remission. After hematopoietic reconstitution, mononuclear cells from donor peripheral blood were collected by hemacytometer in vitro CIK cells were cultured and infused into patients several times to observe the treatment, adverse reactions and prognosis. Results: All of the 9 patients achieved complete remission after hematopoietic reconstitution. After CIK cell infusion, graft-versus-host disease occurred in 4 patients and improved after immunosuppressive therapy. One patient died after 59 days of transplantation Infection, the remaining patients are now in a median follow-up of 9.2 (2 to 20) months and have a good living condition. CONCLUSION: Allo-PBSCT sequential infusion of donor CIK cells has good curative effect, which can save the patients with recurrent / refractory hematological malignancies and is worth further expanding the case study.